Article

Hydralazine as a Repurposed Epigenetic and Metabolic Modulator in Glioblastoma: Promise, Pitfalls, and Future Directions

2026-04-09

Abstract excerpt

Glioblastoma multiforme (GBM) remains one of the most challenging malignancies to treat, characterized by extreme heterogeneity, therapeutic resistance, and a dismal prognosis. Current multimodal treatments frequently fail due to the tumor’s complex epigenetic landscape, infiltrative nature, and a highly hypoxic microenvironment that fosters immune evasion. This review evaluates the potential of repurposing hydral...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 13d49a75-6d9a-5034-b24f-7446eac9f757
DOI: 10.20944/preprints202604.0707.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Hydralazine as a Repurposed Epigenetic and Metabolic Modulator in Glioblastoma: Promise, Pitfalls, and Future DirectionsDOI 10.20944/preprints202604.0707.v1Read

Hydralazine target: From blood vessels to the epigenomeSemantic proximity Read

Hydralazine inhibits cysteamine dioxygenase to treat preeclampsia and senesce glioblastomaSemantic proximity Read

Modified Adenosines Sensitize Glioblastoma Cells to Temozolomide by Affecting DNA MethyltransferasesSemantic proximity Read

Hypotaurine evokes a malignant phenotype in glioma through aberrant hypoxic signaling.Semantic proximity Read

Clinical Pharmacogenetics Implementation Consortium Guideline for NAT2 Genotype and Hydralazine Therapy.Semantic proximity Read

Proton pump inhibitors are detrimental to overall survival of patients with glioblastoma multiforme: results from a nationwide real-world evidence databaseSemantic proximity Read

Phase 1a Evaluation of LP-184 in Recurrent Glioblastoma: Safety, Pharmacokinetics, and Translational Optimization of CNS ExposureSemantic proximity Read

Vasoactivity of AG014699, a Clinically Active Small Molecule Inhibitor of Poly(ADP-ribose) Polymerase: a Contributory Factor to Chemopotentiation In vivo ?Semantic proximity Read

Targeting hexokinase 2 enhances response to radio-chemotherapy in glioblastomaSemantic proximity Read

Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtypeSemantic proximity Read

Activation of dopamine receptor 2 (DRD2) prompts transcriptomic and metabolic plasticity in glioblastomaSemantic proximity Read

Repurposing chlorpromazine as add-on in the adjuvant phase of first-line glioblastoma therapeutic protocol in patients carrying hypo-/un-methylated<i>MGMT</i>gene promoter: RACTAC, a Phase II multicenter single-arm clinical trialSemantic proximity Read